Charlson Comorbidity Index in patients with systemic lupus erythematosus in Egypt and its relation with disease characteristics

Alian, Samah M.; Khalil, Sahar S.; Zaghlol, Rabab S.

doi:10.4103/injr.injr_78_19

Cited by 3 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 In another study from Egypt, they found that CCI scores were significantly higher in patients with steroid intake >10 mg/day, male patients and significantly correlated with the disease duration, SLEDAI, and SDI. 13 Similarly, the main predictors of comorbidity in our cohort were age, disease duration, SLEDAI at onset, cyclophosphamide use, and cumulative methylprednisone.…”

Section: Discussionmentioning

confidence: 67%

“…It was reported to be elevated in patients with SLE. 13 Monitoring, prevention, and management of risk factors for comorbidities are highly recommended by The European Alliance of Associations for Rheumatology. 14 The aim of the present study is to report associated comorbidities among an Egyptian cohort of patients with SLE, its relation to different demographic and disease parameters, and to study the mortality risk in the SLE cohort in context to associated comorbidities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study

et al. 2022

View full text Add to dashboard Cite

Objective To study the prevalence and impact of comorbidities among a cohort of patients with systemic lupus erythematosus (SLE). Methods This study is retrospective, multicenter including 902 Egyptian patients with SLE. Medical records were reviewed for demographic data, clinical characteristics, routine laboratory findings, immunological profile, and medications. Moreover, SLE Disease Activity Index (SLEDAI), and the Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage Index scores were calculated. Results Comorbidities were found in 75.5% of the studied group with hypertension and dyslipidemia as the most frequent comorbidities (43.1% and 40.1%, respectively), followed by sicca features, avascular necrosis, diabetes, osteoporosis and renal failure (11.5%,9%, 9%,8.9%, and 7.1%, respectively). Multivariate regression model showed statistically significant relation between the presence of comorbid condition and each of age ( P = 0.006), disease duration ( P = 0.041), SLEDAI at onset ( P < 0.001), cyclophosphamide intake ( P = 0.001), and cumulative pulse intravenous methylprednisone ( P < 0.001). Also, when adjusted to age and sex, those with multiple comorbid conditions had 18.5 increased odds of mortality compared to those without comorbidities (odds ratio (OR), 95% confidence interval (CI) = 18.5 (6.65–51.69)]. Conclusion Patients with SLE suffer from several comorbidities, with an increasing risk with age, longer disease duration, higher SLEDAI at onset, cyclophosphamide intake and cumulative pulse intravenous methylprednisone. Risk of mortality is exponentiated with multiple comorbidities.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…9 Publications discussing disease related comorbidities and mortality in Africa and specifically in Egypt are relatively scarce. In one study by Alian et al, 2019, 152 SLE patients were assessed from Eastern Egypt, the researchers reported serious infections and hypertension as the most common comorbidities with infection being the most common cause of death. The current study aimed to address the comorbidities associated with SLE and highlight their role in predicting the survival of the patients with SLE following up at the Rheumatology and Rehabilitation department, Kasr Al Ainy Hospital.…”

Section: Discussionmentioning

confidence: 99%

“…In one study by Alian et al, 2019, 152 SLE patients were assessed from Eastern Egypt, the researchers reported serious infections and hypertension as the most common comorbidities with infection being the most common cause of death. 10…”

Section: Discussionmentioning

confidence: 99%

Mortality and disease related comorbidities in systemic lupus erythematosus: Data from an Egyptian cohort

Mohammed

Fayed

Emara

2022

Lupus

View full text Add to dashboard Cite

Background Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with significant disease-related comorbidity and considerably high mortality. Aim of the work Explore the survival rates and the spectrum of disease related comorbidities in an Egyptian cohort afflicted by SLE. Methods This is a single center observational cohort study performed in one of the leading medical Schools governmental hospitals for teaching and training in the North African region and Middle East sectors Kasr Alainy School of Medicine—Cairo University. Inclusion criteria: the investigators of the research question went for planned review of the medical records of adult SLE patients ≥16 years classified according to American College of Rheumatology (ACR) 1997 SLE classification criteria set forth by Hochberg, 1997 who received longitudinal clinical care during the time period from 1999 to 2019. Exclusion criteria: patients seen only once, other collagen vascular diseases, endocrinal, cardiovascular, or other multisystem disease diagnosed prior to the onset of SLE. Data analysis Survival was determined from the time of SLE diagnosis to the last contact or date of death. The cumulative probability of survival was estimated using Kaplan–Meier method. Differences in survival between patient groups were determined using the long-rank test. Results The study included records of two hundred and two SLE patients, 184 (91.1%) were females and 18 (8.9%) patients were males. The mean age at the time of diagnosis was 26.71 ± 7.93 years with a mean follow-up between mean: 6.6 ± 4.58 years, 34.15% had damage in at least one of the organ systems by Systemic Lupus International Collaborating Clinics American college of rheumatology damage index SLICC/ACR-DI in the first 6 months. Considering an outcome label of dead or alive at the end of follow-up period, results showed a total of 52 mortalities, 88.5% were females and 11.5% were males, mean age at death onset was 30.9 ± 8.8 years. Results of the Kaplan–Meier survival curve showed an overall cumulative probability of survival at 5, 10, 15, and 20 years after SLE diagnosis was 82.9, 68.8, 51.4, and 20.4%, respectively. Conclusion The cumulative probability of survival at 5, 10, 15, and 20 years after SLE diagnosis was 82.9, 68.8, 51.4, and 20.4%, respectively.

show abstract

“…Table S3: Characteristics of individual evidence sources related to cardiovascular risk. References [ 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 ] are cited in the Supplementary Materials.…”

mentioning

confidence: 99%

Obesity, Diabetes, and Cardiovascular Risk Burden in Systemic Lupus Erythematosus: Current Approaches and Knowledge Gaps—A Rapid Scoping Review

Hernández-Negrín

Ricci

Mancebo-Sevilla

et al. 2022

IJERPH

View full text Add to dashboard Cite

Obesity, diabetes mellitus, and cardiovascular risk are real challenges in systemic lupus erythematosus (SLE) clinical practice and research. The evidence of the burden of these health problems in SLE patients is determined by the methods used to assess them. Therefore, the aim of this scoping review is to map current approaches in assessing obesity, diabetes mellitus, and cardiovascular risk burden in SLE patients and to identify existing knowledge gaps in this field. This rapid scoping review was conducted according to the Joanna Briggs Institute methodology and identified 274 articles, of which 73 were included. Most studies were conducted at European institutions and patients were recruited from specialist hospital clinics, the majority of whom were women. The burden of obesity and diabetes mellitus for SLE patients was assessed mainly in terms of prevalence, impact on disease activity, and cardiometabolic risk. The burden of cardiovascular risk was assessed using multiple approaches, mainly imaging and laboratory methods, and risk factor-based scores, although there is great heterogeneity and uncertainty between the methods used. This review highlights the importance of improving and standardizing the approach to obesity, diabetes, and cardiovascular risk in SLE patients through a holistic assessment that includes lifestyle, clinical, biological, and social aspects.

show abstract

Charlson Comorbidity Index in patients with systemic lupus erythematosus in Egypt and its relation with disease characteristics

Cited by 3 publications

References 2 publications

Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study

Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study

Mortality and disease related comorbidities in systemic lupus erythematosus: Data from an Egyptian cohort

Obesity, Diabetes, and Cardiovascular Risk Burden in Systemic Lupus Erythematosus: Current Approaches and Knowledge Gaps—A Rapid Scoping Review

Contact Info

Product

Resources

About